Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy are the standard of care approach in the first- or second-line setting for HR+/HER2− advanced breast cancer [5]. This evidence concerns the gene ERBB2 and breast cancer.